What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
The scientist’s investigation covers issues in Cancer research, Ovarian cancer, Molecular biology, Internal medicine and Cancer.
The Cancer research study combines topics in areas such as DNA methylation, Immunology, microRNA, Regulation of gene expression and Gene silencing.
His research in Ovarian cancer intersects with topics in Microarray, Genome-wide association study, Serous fluid and Angiogenesis.
His biological study spans a wide range of topics, including Genetics, Ovary, Serous carcinoma, Ovarian carcinoma and Stage.
His Molecular biology research is multidisciplinary, incorporating elements of Cell culture and JUNB, Transcription factor, c-jun, Transactivation.
His research integrates issues of Gastroenterology, Gynecology and Oncology in his study of Internal medicine.
His most cited work include:
- Integrated genomic analyses of ovarian carcinoma (4769 citations)
- Integrated genomic characterization of endometrial carcinoma (2370 citations)
- Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. (1660 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Ovarian cancer, Internal medicine, Cancer research, Oncology and Cancer.
His study in Ovarian cancer is interdisciplinary in nature, drawing from both Serous fluid, Pathology and Bioinformatics.
His biological study deals with issues like Cell culture, which deal with fields such as Molecular biology.
His Molecular biology research is multidisciplinary, relying on both Regulation of gene expression and Transfection.
His work carried out in the field of Oncology brings together such families of science as Stage, Gynecology, Disease and Epithelial ovarian cancer.
His Cancer research is mostly focused on the topic Breast cancer.
He most often published in these fields:
- Ovarian cancer (44.07%)
- Internal medicine (38.67%)
- Cancer research (33.74%)
What were the highlights of his more recent work (between 2016-2021)?
- Ovarian cancer (44.07%)
- Internal medicine (38.67%)
- Oncology (32.36%)
In recent papers he was focusing on the following fields of study:
Michael J. Birrer mainly focuses on Ovarian cancer, Internal medicine, Oncology, Cancer research and Chemotherapy.
His Ovarian cancer research focuses on Serous fluid and how it relates to Ovarian carcinoma.
In his research, Clinical trial is intimately related to Cancer, which falls under the overarching field of Oncology.
The study incorporates disciplines such as Folate Receptor Alpha, Wnt signaling pathway, Gene and Ovarian tumor in addition to Cancer research.
His studies deal with areas such as Biomarker, Regimen, Peritoneal cancer and Fallopian tube cancer as well as Chemotherapy.
His work deals with themes such as Carboplatin, Platinum sensitive, Carcinoma, Proportional hazards model and Hazard ratio, which intersect with Bevacizumab.
Between 2016 and 2021, his most popular works were:
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (554 citations)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (327 citations)
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy (296 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Michael J. Birrer focuses on Internal medicine, Ovarian cancer, Oncology, Cancer research and Adverse effect.
His research in Internal medicine focuses on subjects like Antibody-drug conjugate, which are connected to Monoclonal, Folate Receptor Alpha, Immunohistochemistry and Tolerability.
Michael J. Birrer interconnects Fluorescence and Pathology in the investigation of issues within Ovarian cancer.
His Oncology study combines topics in areas such as Cancer, Clinical trial and Disease.
His studies in Cancer research integrate themes in fields like DNA methylation, Oncogene, Chromatin, microRNA and Signal transduction.
His Adverse effect research is multidisciplinary, incorporating perspectives in Gastroenterology and Olaparib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
